Rachele Amodeo
Sapienza University of Rome
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rachele Amodeo.
Leukemia & Lymphoma | 2008
Maria Christina Cox; Italo Nofroni; Luigi Ruco; Rachele Amodeo; Antonella Ferrari; Giacinto La Verde; Patrizia Cardelli; Enrico Montefusco; Esmeralda Conte; Bruno Monarca; Maria Antonietta Aloe-Spiriti
The prognostic value of absolute lymphocytic count (ALC), has been a recent matter of debate in non-Hodgkin-lymphoma (NHL). We assessed prospectively the value of ALC at diagnosis and also after the completion of immuno-chemotherapy in 101 diffuse-large-B-cell-lymphoma (DLBCL). Analysis of prognostic factors with respect to overall survival (OS), event free survival (EFS) and progression free survival (PFS) was done by two-tailed log-rank test. The ALC cut-off value was calculated as <0.84 × 109/L at diagnosis: this was a strong negative prognostic factor for OS (p = 0.0004), EFS (p < 0.00001) and PFS (p < 0.00001) and in multivariate analysis was independent from the revised-international-prognostic-index (R-IPI). ALC after chemo-immunotherapy was not of prognostic value. As R-IPI and ALC < 0.84 × 109/L, were the factors better discriminating poor prognosis, a new trichotomous score (ALC/R-IPI) was built up: (1) low risk: R-IPI = very good or good and ALC < 0.84 × 109/L; (2) intermediate risk: patients with at least one risk factor (R-IPI = poor or ALC < 0.84 × 109/L). (3) high risk: patients with both risk factors. This new prognostic score was highly significant in univariate analysis for OS (p = 0.0002), EFS (p < 0.00001) and PFS (p < 0.00001). In multivariate analysis ALC/R-IPI was the most predictive factor for OS (OR = 2.954; p = 0.002) and EFS (OR = 2.381; p < 0.00001) and the only predictive factor for PFS (OR = 4.018; p < 0.00001).Our data, show that ALC at diagnosis has a strong prognostic relevance and is independent from the R-IPI. The new score including both values proved the most powerful predictor at multivariate analysis.
Clinical Immunology | 2010
Simonetta Salemi; Andrea Picchianti-Diamanti; Valentina Germano; Isabella Donatelli; A. Di Martino; Marzia Facchini; Roberto Nisini; Roberto Biselli; C. Ferlito; E. Podestà; A. Cappella; F. Milanetti; F. Rossi; Rachele Amodeo; F. Tabacco; R. Di Rosa; Bruno Laganà; Raffaele D’Amelio
Twenty-eight patients with low-moderate, stable rheumatoid arthritis (RA), under treatment with tumor necrosis factor (TNF) alpha blockers, were immunized at least once with non-adjuvanted trivalent influenza vaccine during three consecutive influenza seasons. Antibodies toward A influenza antigens significantly increased and reached protective levels, still detectable 6 months after vaccination, both in RA patients and healthy controls. Response to B antigen instead was only observed from the second year for healthy controls and in the third year for patients. No significant difference in disease activity and anti-nuclear antibodies was observed as a consequence of vaccine administration, whereas T regulatory cells showed a significant increase 30 days after immunization in RA patients. This study confirms safety of influenza vaccine administration in RA patients treated with TNFalpha blockers. The cohort follow-up revealed the overcoming of poor B vaccine antigen immunogenicity via repeated vaccinations. Finally, protective antibody response was still observed 6 months after vaccination.
British Journal of Haematology | 2008
M. Christina Cox; Italo Nofroni; Giacinto Laverde; Antonella Ferrari; Rachele Amodeo; Caterina Tatarelli; Francesca Saltarelli; Barbara Veggia; M. Antonietta Aloe-Spiriti; Luigi Ruco; Bruno Monarca
imab is associated with a reduction in IgG antibodies to ADAMTS13. British Journal of Haematology, 136, 451–461. Yarranton, H., Lawrie, A.S., MacKie, I.J., Pinkoski, L., Corash, L. & Machin, S.J. (2005) Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion, 45, 1453–1458.
Journal of Cellular Physiology | 2013
Simona Giglio; Roberto Cirombella; Rachele Amodeo; L. Portaro; Luca Lavra; Andrea Vecchione
Cell cycle progression is controlled by numerous mechanisms ensuring correct cell division. The transition from one cell cycle phase to another occurs in an orderly fashion and is regulated by different cellular proteins. Therefore an alteration of the regulatory mechanisms of the cell cycle results in uncontrolled cell proliferation, which is a distinctive feature of human cancers. Recent evidences suggest that microRNAs (miRs) may also control the levels of multiple cell cycle regulators and therefore control cell proliferation. In fact miRs are a class of small non‐coding RNAs, which modulate gene expression. They are involved in numerous physiological cellular processes and most importantly accumulating evidence indicates that many miRs are aberrantly expressed in human cancers. In this report we describe that miR‐24 directly targets p27Kip1 and p16Ink4a in primary keratinocyte and in different cancer derived cell lines promoting their proliferation, suggesting that miR‐24 is involved in cyclin‐dependent kinase inhibitors post‐transcriptional regulation and that upregulation of miR‐24 may play a role in carcinogenesis. J. Cell. Physiol. 228: 2015–2023, 2013.
Annals of Medicine | 2010
Flavia Del Porto; Maria Proietta; Luigi Tritapepe; Fabio Miraldi; Angela Koverech; Patrizia Cardelli; Fabio Tabacco; Vincenzo De Santis; Andrea Vecchione; Anna Paola Mitterhofer; Italo Nofroni; Rachele Amodeo; Trappolini M; Giuseppe Aliberti
Abstract Objective. The aim of our study was to evaluate the lymphocyte subpopulations and the cytokines in the peripheral blood of patients with type-A Stanford acute aortic dissection (AAD group) and to determine whether inflammatory cells are present at the site of aortic dissection. Methods. Thirty-five consecutive patients with type-A Stanford dissection were evaluated for haemochrome and lymphocyte subpopulations (CD3+, CD4+, CD8+, CD19+, CD4+CD25+, CD16+CD56+, CD4+CD28−, CD8+CD28−) by flow cytometry. C-reactive protein (CRP), tumour necrosis factor (TNF)-α, interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, interferon-gamma (IFN-γ), and monocyte chemoattractant protein (MCP)-1 were measured by ELISA. In addition, immunohistochemical staining with cell type-specific antibodies was performed to study the inflammatory cells detected inside the aortic wall. Results. In the AAD group, a significant increase in natural killer (NK) (P = 0.032), B cells (P = 0.022), and CD8+CD28− (P = 0.045) subpopulations was observed, whereas there was a significant decrease in total T lymphocytes (P = 0.004) and T helper fractions (P = 0.005). Moreover, a significant increase in CRP (P < 0.0001), IL-6 (P < 0.0001), IL-8 (P < 0.0001), IL-10 (P < 0.0001), TNF-α (P < 0.0001), and MCP-1 (P < 0.001) was observed; macrophages represented the main population detected inside the media. Conclusions. Our results strongly support the hypothesis of a pivotal role of innate immunity in type-A Stanford AAD.
Immunobiology | 2014
Marco Di Tola; Mariacatia Marino; Rachele Amodeo; Fabio Tabacco; Rossella Casale; L. Portaro; Raffaele Borghini; Antonio Cristaudo; Fedele Manna; Alfredo De Rossi; Ornella De Pità; Patrizia Cardelli; Antonio Picarelli
BACKGROUND The ingestion of nickel (Ni)-rich foods may result in allergic contact mucositis (ACM), a not yet well defined condition identifiable by oral mucosa patch test (omPT). Our aim was to characterize immunologically the ACM taking advantage from the allergen exposure that occurs during the omPT for Ni. METHODS Thirty-seven symptomatic patients underwent to omPT for Ni. Before and after omPT, serum and urine Ni concentrations were determined by mass spectrometry, the white blood cells were counted by hemochromocytometric assay, the peripheral lymphocyte typing was carried out by flow cytometry, total IgE and cytokine serum concentrations were measured by immunoenzymatic assays. The local lymphocyte typing was performed by immunohistochemistry only after omPT. RESULTS According to the omPT outcomes, 25 patients were defined as Ni-sensitive and the remaining 12 as controls. After omPT, serum and urine Ni concentrations increased significantly in all patients, while a significant increment of circulating lymphocytes and neutrophils was highlighted, respectively, in Ni-sensitive and control patients. Consistently, the Th and Tc circulating lymphocytes, as well as the Th/Tc ratio increased significantly in Ni-sensitive patients after omPT. No noteworthy increment in serum concentrations of total IgE and selected cytokines was observed in any patient after omPT. The presence of CD3+, CD4+, and CD8+ cells was highlighted on the oral mucosa biopsy samples taken from Ni-sensitive patients after omPT. CONCLUSIONS In patients with ACM, a local adaptive response with increased lymphocyte trafficking appears to be the most likely mechanism of reaction to Ni administered with the omPT.
Tetrahedron Letters | 1990
Rachele Amodeo; Enrico Baciocchi; Manuela Crescenzi; Osvaldo Lanzalunga
Abstract The oxidation by rat liver microsomes of 4-Z-1,2-dimethylbenzenes (1) and 4-methoxybenzyltrimethylsilane (2) has been investigated. The reaction of the former substrates leads to the expected isomeric benzyl alcohols 3 and 4, with a very low intramolecular selectivity, and only O-demethylation is observed in the reaction of 2. These results suggest the operation of a hydrogen atom transfer mechanism.
Journal of Translational Medicine | 2017
Andrea Picchianti Diamanti; Bruno Laganà; Maria Christina Cox; Emanuela Pilozzi; Rachele Amodeo; Maurizio Bove; Milica Markovic; Roberta Di Rosa; Simonetta Salemi; Maria Laura Sorgi; Maria Manuela Rosado; Raffaele D’Amelio
BackgroundLymphocyte expansion and true lymphocytosis are commonly observed in the everyday clinical practice. The meaning of such phenomenon is often poorly understood so that discrimination between benign and malignant lymphocytosis remains difficult to establish. This is mainly true when lymphocytosis rises in patients affected by immune-mediated chronic inflammatory diseases under immunosuppressive treatment, conditions potentially associated with lymphomagenesis. In this brief report the development of mild T CD4pos lymphocytosis in a group of patients with chronic arthritis under anti-TNF-α treatment is described.MethodsTwo hundred eight rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients have been evaluated longitudinally for at least 1-year before and 2-years after anti-TNF-α therapy introduction for the possible appearance of a lymphocyte expansion. In patients who developed lymphocyte expansion, T, B and NK cells were analysed.ResultsTwenty-five out of 208 (12%) subjects developed a mild T CD4pos lymphocytosis, during anti-TNF-α therapy, which reverted after its interruption. Higher lymphocyte count, more frequent use of steroids and shorter disease duration, before biological therapy start, have emerged as risk factors for lymphocytosis development.ConclusionsThis is the first longitudinal cohort study evaluating the onset of lymphocytosis in RA and PsA patients under anti-TNF-α treatment and its possible clinical relevance. A mild T CD4pos lymphocytosis has been observed in 12% of RA and PsA patients probably related to anti-TNF-α treatment as previously reported by anecdotal cases. Patients with higher baseline lymphocyte count, use of steroids and shorter disease duration before the introduction of biologic therapy, seem to be prone to develop this laboratory reversible abnormality.
Biological Trace Element Research | 2014
Marco Di Tola; Rachele Amodeo; Mariacatia Marino; Fabio Tabacco; Rossella Casale; Maurizio Bove; Alfredo De Rossi; Patrizia Cardelli; Antonio Picarelli
Archive | 2011
Giovanna Ferranti; Patrizia Cardelli; Alfredo Pennica; Antonio Pavan; Fabio Tabacco; C. Della Costanza; Rachele Amodeo; L. Portaro; M.T. Corsetti; S. Battarelli; M. Di Tola; Gerardo Salerno